Nanoformulations for obesity-driven MASLD and MASH: Cell-specific hepatic drug delivery, comorbidity outcomes, and translational perspectives

Obesity Medicine · Published 2026-06-10 · DOI 10.1016/j.obmed.2026.100720

Authors (1)

Polu Picheswara Rao

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Rao, P. (2026). Nanoformulations for obesity-driven MASLD and MASH: Cell-specific hepatic drug delivery, comorbidity outcomes, and translational perspectives. Obesity Medicine. https://doi.org/10.1016/j.obmed.2026.100720

Related articles

• Multidimensional cardiometabolic protection with SGLT2 inhibitors and GLP-1 receptor agonists in obesity, type 2 diabetes and hypertension · Obesity Medicine · 2026 · Same journal
• Rethinking obesity metrics: Cytokines and insulin resistance a better cardiometabolic risk predictor than BMI in young Indian adults · Obesity Medicine · 2026 · Same journal
• Microbiota–gut–brain axis dysregulation in obesity: Neuroimmune-endocrine mechanisms and precision therapeutic targets · Obesity Medicine · 2026 · Same journal
• Advances in GLP-1 receptor agonists: Molecular mechanisms, drug delivery innovations, formulation strategies, and emerging therapeutic applications · Obesity Medicine · 2026 · Same journal
• Improving obesity risk stratification across Asian and European populations: A clinical imperative · Obesity Medicine · 2026 · Same journal
• Factors contributing to non-persistence of glucagon-like peptide-1 agonists: a cross-sectional study · Obesity Medicine · 2025 · Same journal
• Nanotechnology-enabled targeted delivery of incretin therapies for the treatment of obesity and metabolic disorders · Obesity Medicine · 2026 · Same journal
• Optimizing post-bariatric surgery weight management: The role of semaglutide · Obesity Medicine · 2025 · Same journal
• The underestimated axis: Enteroendocrine-Microbiota interactions in obesity pathogenesis and therapy · Obesity Medicine · 2025 · Same journal
• Real-world comparative outcomes of glucagon like peptide-1 receptor agonists and bariatric surgery in inflammatory bowel disease: A multi-center cohort study · Obesity Medicine · 2026 · Same journal